
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is a promising biotechnology company with a unique and innovative approach to developing nanotherapeutics for a wide range of diseases. The company's strong financial position, including a significant cash runway and a recent follow-on offering, provides confidence in its ability to continue its research and development efforts. While facing some risks, including logistical challenges and potential clinical trial setbacks, Nanobiotix's collaboration with JNJ and promising data for its lead program, NBTXR3, position it well for potential commercial success in multiple indications with a significant potential total addressable market size. The recently updated price target of $36, reflecting increased confidence in the company's potential, suggests a positive future outlook for Nanobiotix's stock.
Bears say
Nanobiotix is facing potential challenges with their novel radioenhancer NBTXR3, despite recent positive data updates in stage III unresectable non-small cell lung cancer and locally advanced squamous-cell carcinoma of the head and neck. There are also risks associated with potential product failures, legal issues, and competition. The recent patent applications for the Curadigm platform provide some potential for future growth, but the company still faces overall risks in their research, development, and regulatory processes. Financially, the company relies on funding from partnerships and dilutive financing, which could lead to lower-than-expected sales and financial results.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares